These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 17457926)

  • 41. Development of a novel vaccinia-neutralization assay based on reporter-gene expression.
    Manischewitz J; King LR; Bleckwenn NA; Shiloach J; Taffs R; Merchlinsky M; Eller N; Mikolajczyk MG; Clanton DJ; Monath T; Weltzin RA; Scott DE; Golding H
    J Infect Dis; 2003 Aug; 188(3):440-8. PubMed ID: 12870127
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.
    Ferrier-Rembert A; Drillien R; Meignier B; Garin D; Crance JM
    Vaccine; 2007 Nov; 25(49):8290-7. PubMed ID: 17964011
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.
    Kreijtz JH; Suezer Y; van Amerongen G; de Mutsert G; Schnierle BS; Wood JM; Kuiken T; Fouchier RA; Lower J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    J Infect Dis; 2007 Jun; 195(11):1598-606. PubMed ID: 17471429
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical development of Modified Vaccinia virus Ankara vaccines.
    Gilbert SC
    Vaccine; 2013 Sep; 31(39):4241-6. PubMed ID: 23523410
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.
    Bejon P; Mwacharo J; Kai OK; Todryk S; Keating S; Lang T; Gilbert SC; Peshu N; Marsh K; Hill AV
    Vaccine; 2006 May; 24(22):4709-15. PubMed ID: 16621181
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
    Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
    J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Construction and biological characteristic for the recombinant modified vaccinia virus ankara co-expressing modified GP5 and M protein of porcine reproductive and respiratory syndrome virus].
    Zheng Q; Li P; Cao R; Hou J; Chen P
    Sheng Wu Gong Cheng Xue Bao; 2008 May; 24(5):766-73. PubMed ID: 18724695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sequence and phylogenetic analysis of host-range (E3L, K3L, and C7L) and structural protein (B5R) genes of buffalopox virus isolates from buffalo, cattle, and human in India.
    Bera BCh; Shanmugasundaram K; Barua S; Anand T; Riyesh T; Vaid RK; Virmani N; Bansal M; Shukla BN; Malik P; Singh RK
    Virus Genes; 2012 Dec; 45(3):488-98. PubMed ID: 22872567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.
    Jones T
    Curr Opin Mol Ther; 2008 Aug; 10(4):407-17. PubMed ID: 18683106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge.
    Vliegen I; Yang G; Hruby D; Jordan R; Neyts J
    Antiviral Res; 2012 Jan; 93(1):160-6. PubMed ID: 22138484
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks.
    Handley L; Buller RM; Frey SE; Bellone C; Parker S
    Expert Rev Vaccines; 2009 Jul; 8(7):841-50. PubMed ID: 19538111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High level protein expression in mammalian cells using a safe viral vector: modified vaccinia virus Ankara.
    Hebben M; Brants J; Birck C; Samama JP; Wasylyk B; Spehner D; Pradeau K; Domi A; Moss B; Schultz P; Drillien R
    Protein Expr Purif; 2007 Dec; 56(2):269-78. PubMed ID: 17892951
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine.
    Weltzin R; Liu J; Pugachev KV; Myers GA; Coughlin B; Blum PS; Nichols R; Johnson C; Cruz J; Kennedy JS; Ennis FA; Monath TP
    Nat Med; 2003 Sep; 9(9):1125-30. PubMed ID: 12925845
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunization of rabbits with a modified vaccinia Ankara recombinant virus bearing the HIV envelope antigen on its outer membrane.
    Barchichat S; Katz E
    Virus Res; 2002 Dec; 90(1-2):243-51. PubMed ID: 12457978
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Substitution of vaccinia virus Elstree by modified vaccinia virus Ankara to test the virucidal efficacy of chemical disinfectants.
    Hartnack S; Essbauer S; Truyen U
    Zoonoses Public Health; 2008; 55(2):99-105. PubMed ID: 18234028
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The vaccinia virus bifunctional gene J3 (nucleoside-2'-O-)-methyltransferase and poly(A) polymerase stimulatory factor is implicated as a positive transcription elongation factor by two genetic approaches.
    Latner DR; Xiang Y; Lewis JI; Condit J; Condit RC
    Virology; 2000 Apr; 269(2):345-55. PubMed ID: 10753713
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neutralizing epitope on penetration protein of vaccinia virus.
    Ichihashi Y; Oie M
    Virology; 1996 Jun; 220(2):491-4. PubMed ID: 8661400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic stability of recombinant MVA-BN.
    Timm A; Enzinger C; Felder E; Chaplin P
    Vaccine; 2006 May; 24(21):4618-21. PubMed ID: 16157428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interaction between vaccinia virus extracellular virus envelope A33 and B5 glycoproteins.
    Perdiguero B; Blasco R
    J Virol; 2006 Sep; 80(17):8763-77. PubMed ID: 16912323
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.
    Kidokoro M; Tashiro M; Shida H
    Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4152-7. PubMed ID: 15753319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.